Once Upon a Farm Enters Electrolytes, GLP-1 Rewires Retail

Once Upon a Farm launches kids' organic electrolytes, GLP-1 drugs reshape retail strategy, vitamin D targets pancreatic cancer, and diet drinks match water for weight loss.

Show Notes

Once Upon a Farm is coming for the electrolyte aisle with an organic kids' range — and GLP-1 drugs are forcing retailers from grocers to apparel brands to rethink everything. Two shifts supplement and functional food founders need to understand today.

In this episode:

• New oncology research shows a vitamin D analog can break down the protective stromal barrier surrounding pancreatic tumours, adding clinical depth to vitamin D's biological story without making any cancer claim.
• Once Upon a Farm, the celebrity-backed organic kids' food brand, is launching organic electrolyte powder blends as part of a deliberate cradle-to-childhood lifecycle nutrition strategy, targeting a white space adult brands like LMNT and Liquid I.V. have left open.
• Retail Dive reports that GLP-1 drug users are forcing systemic changes across retail categories including apparel and grocery, with supplement brands well-placed to address the protein, micronutrient, and muscle-preservation gaps created by reduced food intake.
• A two-year randomised clinical trial of 493 adults found diet soft drinks were as effective as water for weight loss, directly challenging consumer scepticism about artificial sweeteners and giving functional beverage brands significant new credibility.

The Health Marketing Daily is a concise briefing for marketers and founders in supplements, functional food and consumer health, hosted by Marco & Klara. New episode every day.

Enjoying the show? A quick rating or review on Apple Podcasts or Spotify helps other marketers find us.

Also from Marco & Klara: The FMCG Marketing Daily · The Digital Commerce Daily

What is The Health Marketing Daily?

The daily briefing for professionals in health, nutrition, and wellness marketing. Every episode covers an ingredient of the day, the latest science and regulatory updates from EFSA and beyond, and the brand and market moves shaping the nutraceutical industry. Hosted by Klara and Marco — evidence-based, no hype, no bro-science. Built for formulators, brand managers, regulatory affairs teams, and anyone building in the health and nutrition space.

Marco: Four strong stories today — we're not easing in gently.
Klara: Vitamin D turning up in pancreatic cancer research, which is going to raise some eyebrows in the supplement world.
Marco: Kids' electrolytes are officially a thing — Once Upon a Farm is making the move.
Klara: GLP-1 drugs are rewriting retail strategy in ways nobody predicted.
Marco: And diet drinks versus water for weight loss — a proper clinical trial with real implications.
Klara: Let's get into it.

Marco: Scientists may have found a way to use a vitamin D compound to break through one of cancer's toughest defences.

Marco: Pancreatic cancer is notoriously hard to treat. One reason is that tumours surround themselves with a dense layer of protective tissue called the stroma. Think of it like a fortress wall that keeps treatments out.

Marco: New research published via Science Daily Health shows that a vitamin D analog — that's a synthetic compound that mimics vitamin D's behaviour in the body — can break down that stromal barrier around pancreatic tumours. The hope is that once the wall comes down, chemotherapy and the immune system can actually reach the cancer cells.

Klara: This is genuinely significant research. Vitamin D receptors are found throughout the body, including in tumour-adjacent tissue. The fact that a vitamin D-derived compound can interact with that stromal layer tells us there's real biology here worth exploring. This isn't a supplement study — it's oncology research. That distinction matters enormously.

Marco: And for supplement brands, that distinction is exactly what makes this useful. You can't make cancer claims. EFSA — the EU's food safety authority — would shut that down immediately. But peer-reviewed oncology research keeps confirming that vitamin D operates at a profound biological level. That credibility is bankable for premium positioning.

Klara: I'd be cautious though. A vitamin D analog is not the same as standard vitamin D3 you find on a shelf in Holland & Barrett. The molecular structure may be quite different. Marketers who blur that line are misrepresenting the science.

Marco: Completely fair. The story to tell is about vitamin D's biological depth — not a cure claim.

Klara: Watch this space into 2027. The research pipeline here is building momentum.

Marco: Now, let's move to our next story.

Klara: A kids' food brand best known for pouches and purees is now coming for the electrolyte aisle.

Klara: Once Upon a Farm has built its reputation on organic, clean-label nutrition for babies and young children. The brand has celebrity backing and strong retail presence in the US. Its core proposition has always been trust — parents know what's in it, and they feel good about it.

Klara: The news is that Once Upon a Farm is launching organic electrolyte powder blends, explicitly framed as part of a cradle-to-childhood nutrition strategy. The target is parents who want a clean alternative to adult-oriented products like LMNT or Liquid I.V. — brands that were never designed with children in mind.

Klara: From a formulation standpoint, this is worth watching carefully. Electrolyte needs in children differ meaningfully from adults. Sodium, potassium, and magnesium ratios matter — and so do sweeteners. Many adult electrolyte products use ingredients that aren't appropriate for young children. If Once Upon a Farm gets the formulation right for a paediatric audience, that's a legitimate gap being filled.

Marco: Commercially, this is a very smart move. The electrolyte category has exploded, but it's almost entirely adult-facing. The family wellness segment is underserved and parents are actively looking for products they can trust for their kids. Once Upon a Farm already has that trust. Extending it into functional hydration is lower risk than building a new brand from scratch.

Klara: I'd want to see clinical backing specific to children though. Reformulating for a younger audience isn't just a label change — it requires proper nutritional justification.

Marco: Agreed. The brand equity is strong, but the science needs to follow.

Klara: Lifecycle brand architecture is becoming a real competitive advantage. This is a clear example of it in action. Now, let's move to our next story.

Marco: GLP-1 drugs aren't just changing waistlines — they're rewiring how retailers think about entire product categories.

Marco: GLP-1s are prescription weight loss medications like semaglutide — sold as Wegovy and Ozempic — that suppress appetite and reduce calorie intake significantly. Adoption is accelerating fast across Europe and the US. And as more people use them, their spending behaviour is shifting in ways retailers are only beginning to map.

Marco: Retail Dive is reporting that retailers across food, supplements, and even apparel are actively restructuring their assortments and sizing strategies in direct response to this growing consumer cohort. This isn't a niche adjustment. It's systemic. Clothing brands are rethinking size ranges. Grocery retailers are reconfiguring what gets shelf space. The ripple effects are moving far beyond the pharmacy.

Marco: For supplement and functional food brands, the commercial opportunity here is significant. GLP-1 users eat less — but that creates real nutritional gaps. Lower food intake means lower protein, fewer micronutrients, and risk of muscle loss. These are addressable gaps. Protein supplements, electrolytes, vitamin D, B12 — these categories all become genuinely relevant for this cohort.

Klara: The nutritional risks are real. Studies do show muscle mass loss is a documented concern with GLP-1 use. So protein and leucine intake — leucine is an amino acid that specifically supports muscle protein synthesis — become genuinely important. The science supports those conversations.

Marco: And brands that start positioning now will be embedded in this category before it gets crowded.

Klara: My concern is that some brands will chase GLP-1 positioning without formulations that actually match the need. Slapping a label on a standard protein powder is not a strategy.

Marco: Differentiation has to come from the product first, then the story.

Klara: Let's move to our final story for today.

Klara: A major two-year trial has found that diet soft drinks are just as effective as water when it comes to weight loss.

Klara: Consumer scepticism about artificial sweeteners has been a persistent headwind for the low-calorie drinks category. Concerns range from gut microbiome disruption to cravings stimulation — and while much of that was based on smaller, observational studies, the narrative stuck. Brands in this space have been fighting that perception for years.

Klara: This new trial, reported via Science Daily Health, followed 493 adults with overweight or obesity over two years. It was a randomised clinical trial — meaning participants were deliberately assigned to conditions, which is a much stronger study design than simply observing people's habits. The result: diet soft drinks produced essentially equivalent weight loss outcomes to water.

Klara: That's a meaningful finding. The study's duration and scale lift it above the noise. Two years is a serious timeframe for a nutrition trial — long enough to capture real behavioural patterns, not just short-term effects. The sweetener-equals-weight-gain narrative has relied heavily on weaker evidence. This data cuts against it clearly.

Marco: For low-calorie and functional beverage brands, this is a genuine vindication. But I'd actually argue the bigger challenge now is communication, not formulation. Because consumers have absorbed the anti-sweetener story deeply. A single study won't flip that overnight.

Klara: And this is where I'd push a different direction to you, Marco. The temptation will be to lead with "clinically proven" messaging around this trial. But EFSA's standards for authorised health claims are strict — a single trial, however well-designed, doesn't clear that bar. Brands need to be careful not to overreach.

Marco: Which means the smarter play is using this as a foundation for a broader credibility narrative — not a headline claim. The brands that navigate that nuance will pull ahead.

Marco: Today's thread is clear — health science is moving faster than most brands' regulatory playbooks, and the brands that close that gap will own the shelf.
Klara: Know what your evidence actually supports, and claim exactly that — nothing more.
Marco: The gap between what science shows and what marketing says is where trust gets lost.